Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):150-153
DOI: 10.5428/pcar20190219
One case analysis of clopidogrel resistance combined with ticagrelor allergy
1. CHANG Zhenzhen(a changzhenzhen001@163.com)
Welcome to PCAR! You are the number 46 reader of this article!
Please cite this article as:
CHANG Zhenzhen,. One case analysis of clopidogrel resistance combined with ticagrelor allergy[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 150-153.
References:
1. Cardio-Cerebrovascular Diseases Professional Committee of China Gerontological Society,Cardio-Cerebrovascular Diseases Professional Committee of Chinese Rehabilitation Medicine Association. Chinese expert consensus on the treatment of stable coronary artery disease by oral antiplatelet drugs[J]. Chin J Cardiol,2016,44(2): 104-111. In Chinese.
2. Branch of Cardiovascular Diseases,Chinese Medical Association;Editorial Board of Chinese Journal of Cardiology. Chinese expert advice on clinical detection and treatment of antiplatelet therapy response diversity[J]. Chin J Cardiol,2014,42(12):986-991.In Chinese.
3. Mehta S R,Bainey K R,Cantor W J,et al.2018 Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) focused update of the guidelines for the use of antiplatelet therapy[J]. Can J Cardiol,2018,34(3):214-233.
4. HUI Gang,SONG Dandan,QI Chao,et al.Application of single gene polymorphism in the diagnosis of cardiovascular diseases[J].Chin J Lab Diagn,2018,22(3):543-546.In Chinese.
5. Thrombosis Prevention and Therapy Professional Committee of Branch of Cardiovascular Physicians,Chinese Medical Doctor Association; Interventional Group of Branch of Cardiovascular Diseases,Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Chinese expert consensus on clinical application of ticagrelor[J]. Chin J Cardiol,2016,44(2):112-120. In Chinese.
6. Wallentin L,James S,Storey R F,et al.Effect of CYP2C19 and ABCBl single nucleotide polymorphisms on the outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial [J].Lancet,2010,376:1320-1328.
7. CHEN Yundai,DONG Wei,WAN Zheng,et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome:a pharmacodynamic analysis[J].Int J Cardiol,2015,201:545-546.
8. LI Zhihua,ZHANG Yachen,XIE Yuquan,et al.Clinical efficacy and safety of ticagrelor in acute coronary syndrome patients receiving percutaneous coronary intervention [J].Chin J Intervent Cardiol,2015,23(8):446-450.In Chinese with English abstract.
9. ZHANG Jianhong,ZHU Liqin,TIAN Danli,et al.Adverse drug reactions induced by ticagrelor:an analysis of domestic and foreign literature[J]. Chin J New Drugs,2017,26 (11):1335-1338. In Chinese with English abstract.
10. Ikram S,Veerappan Kandasamy V.Ticagrelor-induced sweet syndrome: an unusual dermatologic complication after percutaneous coronary intervention [J]. Cardiovasc Interv Ther,2017,32(3):244-246.
11. TU Qiang,CAO Zheng. Progress in the pharmacological effect and clinical application of cilostazol[J]. Chin J Arterioscler,2017,25(6):644-648. In Chinese with English abstract.
12. HAN Yaling,LI Yi,WANG Shouli,et al.Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes:a randomized,controlled study[J].Am Heart J,2009,157(4):733-739.
13. ZHANG Bin,CHU Zhenliang,JIANG Liqin,et al. Effect of cilostazol on ACS patients carrying CYP2C19*2 gene associated with high on-treatment platelet reactivity[J]. Prevent Treat Cardio-Cereb-Vasc Dis,2017,17(5):344-346,363. In Chinese with English abstract.
14. Johnson D A,Katz P O,Armstrong D,et al.The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus[J].Drugs,2017,77(5):547-561.
15. Evaluation Working Group of Statin Safety. Expert consensus on statin safety evaluation[J]. Chin J Cardiol,2014,42(11):890-894.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口